Skip to Content
Søg Menu
Vi dækker

ASCO | American Society of Clinical Oncology

ASCO 2025

Behandling af metastatisk nyrecancer – Data fra 25 års erfaring

/ Niels Fristrup
ASCO21NyrecancerImmunterapi Play the Video

Per Pfeiffer

1. linje encorafenib/cetuximab + kemo øger OS ved BRAF-mut. mCRC

/ Per Pfeiffer
ASCO25Kolorektal cancer Play the Video
Andreas Koulouris

Lung Cancer: Even Small Tumor Volumes Worsen Prognosis and Increase Risk of Complications After SRS

/ Andreas Koulouris
ASCO25 Play the Video
Jean Bourhis

ASCO 2025: Nivolumab + chemoradiotherapy improves disease-free survival in Head and Neck Cancer

/ Jean Bourhis
ASCO25Kolorektal cancer Play the Video
Johanne Dam Lyhne

ASCO 2025: Internetbaseret intervention mindsker frygt for tilbagefald ved tarmkræft

/ Johanne Dam Lyhne
ASCO25Kolorektal cancer Play the Video
Inna Markovna Chen

ASCO 2025: Chemo-Immunotherapy Combined with Stereotactic Radiation Shows Promise in Pancreatic Cancer

/ Inna Markovna Chen
ASCO25 Play the Video
Sara Tolaney

ASCO 2025: Redefining First-Line Therapy in HER2+ Breast Cancer with T-DXd and Pertuzumab

/ Sara Tolaney
ASCO25NBCNBrystcancer Play the Video

Toward a New Standard of Care: Sacituzumab and Pembrolizumab in PD-L1+ mTNBC

/ Jan Andreasen
ASCO25NBCN
Bjørn Henning Grønberg

Immunotherapy after chemoradiotherapy did not improve PFS or OS in limited stage SCLC

/ Bjørn Henning Grønberg
ASCO25 Play the Video
Laurids Østergaard Poulsen

Markant forbedret overlevelse ved metastatisk kolorektalcancer med BRAF V600E mutation

/ Laurids Østergaard Poulsen
ASCO25Kolorektal cancer Play the Video

Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma

/ Ghassan Abou-Alfa
CancerASCO21 Play the Video

Relatlimab + nivolumab: En ny potentiel kombination af førstelinjebehandling af avanceret melanoma

/ Marco Donia
MelanomASCO21 Play the Video
Hent flere

ASCO 2024

Thorgerdur Palsdottir

The Capio Model for Prostate Cancer Diagnostics

/ Thorgerdur Palsdottir
ASCO24Prostatacancer Play the Video

Joaquim Bellmunt

First-Line Maintenance Therapy with Avelumab Show Significantly Prolonged OS and PFS in Patients with Advanced Urothelial Cancer with Low Tumor Burden

/ Joaquim Bellmunt
ASCO24Blærecancer Play the Video
Cathy Burton

Paradigm Changes in Hodgkin’s Lymphoma Treatments

/ Cathy Burton
ASCO24Hodgkins lymfomLymfom Play the Video
Oluf Dimitri Røe

ASCO24: Very Exciting Steps for Early Diagnosis and Lung Cancer

/ Oluf Dimitri Røe
ASCO24Lungecancer Play the Video

Trastuzumab Deruxtecan Significantly Improves Progression-Free Survival in Breast Cancer Patients Previously Treated with Endocrine Therapy

/ Sofie Pohl
ASCO24
Oluf Dimitri Røe

Oluf Dimitri Røe: ASCO Is the Cradle of Oncology

/ Oluf Dimitri Røe
ASCO24 Play the Video

Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma

/ Ghassan Abou-Alfa
CancerASCO21 Play the Video
Hent flere

ASCO 2023

Highlights fra ASCO 2023: Nye indsigter i luminal brystkræft

/ Bent Ejlertsen
ASCO23Brystcancer
Oluf Dimitri Røe

Can We Predict Bladder Cancer Using the HUNT Model?

/ Oluf Dimitri Røe
ASCO23Blærecancer Play the Video
Stine Bakkensen Bruun

Circulating Methylated-HOXA9 Tumor DNA as a Biomarker in Recurrent Breast Cancer

/ Stine Bakkensen Bruun
ASCO23Brystcancer Play the Video
Bent Ejlertsen

Hvad var nyt på ASCO23 inden for brystcancer?

/ Bent Ejlertsen
ASCO23 Play the Video
Lars Henrik Jensen

Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Does Not Change OS

/ Lars Henrik Jensen
ASCO23Tarmcancer Play the Video

Significant PFS Benefit for the Nivolumab + Relatlimab Combination for Patients with Unresectable or Metastatic Melanoma

/ BestPractice Nordic
ASCO23Melanom
Hent flere

ASCO 2022

Jeanne Tie

The randomized DYNAMIC Trial: ctDNA-guided approach towards adjuvant chemotherapy

/ Jeanne Tie
ASCO22Kolorektal cancer Play the Video
David Cella, Dr

HRQoL as Prognostic Value for Overall Survival in Patients with RCC Receiving ICIs

/ David Cella
ASCO22Nyrecancer Play the Video

Novel Agent Increases PFS for Patients with endocrine-resistant HR+/HER2- metastatic breast cancer

/ BestPractice Nordic
HER2ASCO22Brystcancer

Ibrutinib added to Standard-of-Care Therapy improves PFS by 50% for Older Patients with Newly Diagnosed Mantle Cell Lymphoma

/ BestPractice Nordic
ASCO22Lymfom

Health-related quality of life is associated with clinical outcomes in patients with advanced renal cell carcinoma

/ BestPractice Nordic
ASCO22Nyrecancer

Nivolumab in combination with relatlimab significantly improved PFS in patients with previously untreated metastatic or unresectable melanoma

/ BestPractice Nordic
ASCO22Hudcancer

First-line treatment with Relatlima + nivolumab demonstrated significant PFS benefit in patients with advanced melanoma

/ Evan J. Lipson
MelanomASCO21 Play the Video

Significantly improved pathological complete response with nivolumab + chemotherapy in NSCLC

/ Jonathan Spicer
NSCLCASCO21 Play the Video

Potentiel førstelinjebehandling ved avanceret renalcellecarcinom

/ BestPractice Nordic
ASCO21Nyrecancer
Woman with cancer looking at x-ray

Neoadjuvant nivolumab + kemoterapi forbedrer komplet patologisk responsrate og forkorter operationstid uanset stadie af NSCLC

/ BestPractice Nordic
NSCLCLungecancerASCO21

Se tidligere dækning af ASCO 2021 og 2020

Man at the doctor

Radioligand reducerer risikoen for progression og død for patienter med metastatisk kastrationsresistent prostatacancer

/ BestPractice Nordic
ASCO21Prostatacancer
Self Diagnosis Of Early Breast Cancer

Olaparib kan ændre klinisk praksis i adjuverende behandling af brystcancer

/ BestPractice Nordic
BrystcancerASCO21
Tværsnit af en nyre

KEYNOTE-564 viser lovende resultater for adjuverende behandling med pembrolizumab til højrisiko nyrekræft

/ BestPractice Nordic
ASCO21Nyrecancer
Lung Cancer

Bliver atezolizumab ny standard for adjuverende behandling af patienter med NSCLC?

/ BestPractice Nordic
NSCLCLungecancerASCO21
Læge ser på røntgenfotografi af patient

Immunrelaterede bivirkninger ved atezolizumab har sammenhæng med bedre overlevelse for patienter med NSCLC

/ BestPractice Nordic
NSCLCLungecancerASCO21

Nivolumab plus cabozantinib i 1. linje fordobler PFS ved avanceret renalcellecarcinom – på tværs af subgrupper

/ BestPractice Nordic
ASCO21Nyrecancer
Mere

Back to top